Studies with AR in prostate cancer suggest that the AR cistrome is broadly reprogrammed during tumorigenesis (Pomerantz et al., 2015), supporting a model in which nuclear receptors take on de novo target regulation in transformed cells. This evidence concerns the gene AR and prostate cancer.